Image Source: Fox Business
A side effect linked to popular GLP-1 medications has prompted the Food and Drug Administration to require new warning labels on Ozempic, Wegovy and other drugs used to treat diabetes, obesity and related conditions.
The FDA announced the labeling action on November 10, 2026, after reviewing 126 clinical trials involving 134,253 patients. The agency said the medications may be associated with a small increased risk of non-arteritic anterior ischemic optic neuropathy, a rare eye condition that can cause significant or permanent vision loss.
FDA Reveals Rare Side Effect Risk for Ozempic and Wegovy
Non-arteritic anterior ischemic optic neuropathy, commonly known as NAION, occurs when blood flow to the optic nerve is reduced. The condition typically appears suddenly and without pain, often affecting one eye after a person wakes up.
Possible symptoms include blurred vision, blind spots and changes in color perception. There is currently no proven treatment that can reliably reverse the damage, although some patients experience partial improvement over time.
The FDA’s analysis found approximately six cases of NAION per 100,000 patients taking GLP-1 drugs over a one-year period. That compared with fewer than four cases among patients taking a placebo or other glucose-lowering medications.
Overall, patients taking GLP-1 drugs had an approximately 68% higher rate of the eye condition. However, the FDA emphasized that the findings do not prove the medications caused the vision loss.
Why the Evidence Remains Complicated
FDA scientists began examining the potential connection in 2024 after research identified cases involving semaglutide, the active ingredient in Ozempic and Wegovy. The agency’s review included a broad collection of clinical trial data, but investigators said several factors made the results difficult to interpret.
Diabetes, high blood pressure and sleep apnea are recognized risk factors for NAION. Those same conditions are also common among people who receive GLP-1 prescriptions, creating uncertainty about whether the drugs themselves are responsible for the increased incidence.
Of approximately 78,000 patients included in the studies used for part of the FDA’s evaluation, only 10 experienced vision loss associated with the condition. That represents roughly 0.01% of the participants reviewed.
Although the risk remains very low, the FDA determined that the information was important enough to require updated warnings across the GLP-1 drug class. The label changes apply to both injectable and pill-based treatments.
What Patients Taking GLP-1 Drugs Should Know
The new warning does not mean patients should automatically stop taking Ozempic, Wegovy or another prescribed GLP-1 medication. These drugs remain widely used for blood sugar control and weight management, and the FDA’s findings do not establish a definitive cause-and-effect relationship.
- Sudden vision changes should be treated as a medical concern.
- Blurred vision, blind spots or altered color perception may require prompt evaluation.
- Patients should discuss personal risk factors with their healthcare provider.
- People should not discontinue a prescription without medical guidance.
NAION is most common among adults over age 50. Research cited by the FDA indicates that approximately 43% of patients with significant visual impairment may experience some spontaneous improvement, although defects in the visual field can remain.
The agency’s decision adds another safety consideration to the fast-growing GLP-1 medication market. Ozempic and Wegovy have become household names as demand for diabetes and weight-loss treatments has surged, while other manufacturers continue developing competing products.
Warning Labels Aim to Improve Awareness
Updated labels are designed to help doctors and patients recognize the potential warning signs early. The FDA said the action reflects ongoing monitoring of medications after they reach the market, rather than a finding that the treatments should be withdrawn.
For users, the key message is awareness. A sudden, painless change in vision can have many possible causes, but it should not be ignored. Prompt communication with a healthcare professional may help determine whether the symptoms are related to NAION or another urgent eye problem.
Frequently Asked Questions
What is the side effect connected to Ozempic and Wegovy?
The FDA is warning about a possible association with non-arteritic anterior ischemic optic neuropathy, a rare eye condition that can cause sudden vision loss.
How common is this vision-related side effect?
The FDA found approximately six cases per 100,000 GLP-1 users over one year, compared with fewer than four cases among people receiving certain alternatives or a placebo.
Does the FDA say Ozempic causes permanent blindness?
No. The agency said the evidence does not establish a causal link. However, NAION can cause significant or permanent vision loss in some patients.
Should patients stop taking GLP-1 medications?
Patients should not stop a prescribed medication without speaking with their healthcare provider. Anyone experiencing sudden vision changes should seek prompt medical evaluation.
